'As expected, there have been hiccups along the way. Last...

'As expected, there have been hiccups along the way. Last August, the New York-based biotech announced topline data from a phase 2 study of OV101, its Angelman program. The data came from 88 patients after 12 weeks of treatment and showed that OV101 beat placebo on one measure but failed to do so on 16 other metrics.'

This kind of says it all, going on to P3 with only 1 of 16 hits in primary outcomes at P2 is, let's say, bold, in my view.

It is worth reading up about Tonic inhibition and the role of UBE3A in Angelman's, a task I've just started, with thanks to Piton and Hottod.